As of Mar 27
| +0.26 / +3.59%|
The 7 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 11.00, with a high estimate of 15.00 and a low estimate of 8.00. The median estimate represents a +46.67% increase from the last price of 7.50.
The current consensus among 7 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.